Smoldering Multiple Myeloma Clinical Trial
Official title:
Aggressive Smoldering Curative Approach Evaluating Novel Therapies (ASCENT): A Phase 2 Trial of Induction, Consolidation, and Maintenance in Subjects With High Risk Smoldering Multiple Myeloma (SMM)
This study evaluates the use of carfilzomib, lenalidomide, daratumumab, and dexamethasone in subjects with high-risk smoldering multiple myeloma (SMM). Subjects will receive treatment in 3 phases - induction (6 cycles), consolidation (6 cycles), and maintenance (12 cycles). Each cycle is 28 days.
This study is a multi-center phase 2 study of carfilzomib, lenalidomide, daratumumab, and dexamethasone in subjects with high-risk smoldering multiple myeloma (SMM). Myeloma remains incurable with the current approaches. The typical natural history of myeloma is one of repeated relapses, accompanied by genetic evolution and development of new abnormalities, which are often responsible for drug resistance. The presence of a precursor phase of smoldering myeloma, and the ability to identify those at the highest risk of progression, sets the stage to examine the possibility that we can cure the disease through early intervention. In order to potentially achieve this, we need to develop a highly effective combination that includes the most active drugs from different classes. Carfilzomib in combination with lenalidomide and dexamethasone results in high response rates and deep responses in subjects with newly diagnosed myeloma. Daratumumab in combination with lenalidomide results in high response rates in relapsed refractory disease. All these drugs are well tolerated and subjects are able to stay on them long term as a maintenance treatment. The combination of the carfilzomib, lenalidomide, daratumumab and dexamethasone presents the potential to enhance the effectiveness of the regimens. We hypothesize that this combination will lead to deep response including a higher proportion of minimal residual disease (MRD) negative disease among those with high risk smoldering myeloma and may translate into cure or long term disease quiescence. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01222286 -
Study on the Anti-tumor Activity, Safety and Pharmacology of IPH2101 in Patients With Smoldering Multiple Myeloma
|
Phase 2 | |
Withdrawn |
NCT00503763 -
Efficacy and Safety of Statin on the Course of Progressive Smoldering Multiple Myeloma
|
Phase 2 | |
Active, not recruiting |
NCT02916771 -
Trial of Combination of Ixazomib and Lenalidomide and Dexamethasone in Smoldering Multiple Myeloma
|
Phase 2 | |
Completed |
NCT01955395 -
Genomic and Psychosocial Effects of the 3RP on Patients With MGUS and Smoldering Multiple Myeloma
|
N/A | |
Completed |
NCT01237054 -
Imaging in MGUS, SMM and MM
|
Phase 2 | |
Completed |
NCT02903381 -
A Phase II Trial If Nivolumab, Lenalidomide and Dexamethasone in High Risk Smoldering Myeloma
|
Phase 2 | |
Active, not recruiting |
NCT03301220 -
A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma
|
Phase 3 | |
Active, not recruiting |
NCT03236428 -
Phase II Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma
|
Phase 2 | |
Completed |
NCT01718899 -
Phase 1/2a Study of Cancer Vaccine to Treat Smoldering Multiple Myeloma
|
Phase 1 | |
Completed |
NCT00099047 -
Celecoxib in Preventing Multiple Myeloma in Patients With Monoclonal Gammopathy or Smoldering Myeloma
|
Phase 2 | |
Completed |
NCT00112827 -
Melphalan and Radiation Therapy Followed By Lenalidomide in Treating Patients Who Are Undergoing Autologous Stem Cell Transplant for Stage I, Stage II, or Stage III Multiple Myeloma
|
Phase 1/Phase 2 | |
Terminated |
NCT01248455 -
A Phase II Trial of Anti-KIR in Smoldering Multiple Myeloma
|
Phase 2 | |
Not yet recruiting |
NCT06365060 -
Screening for AL Amyloidosis in Smoldering Multiple Myeloma
|
||
Active, not recruiting |
NCT02415413 -
Carfilzomib in Treatment Patients Under 65 Years With High Risk Smoldering Multiple Myeloma
|
Phase 2 | |
Completed |
NCT01302886 -
Study of BHQ880 in Patients With High Risk Smoldering Multiple Myeloma
|
Phase 2 | |
Recruiting |
NCT05841550 -
The TG01 Study With TG01/QS-21 Vaccine in Patients With High-risk Smouldering Multiple Myeloma and Multiple Myeloma
|
Phase 1/Phase 2 | |
Recruiting |
NCT06183489 -
Use of Elranatamab in Patients With High-risk Smoldering Multiple Myeloma
|
Phase 2 | |
Recruiting |
NCT06383143 -
Promoting Diagnosis and Management of AL in Italy (ProDigALIty)
|
||
Active, not recruiting |
NCT02886065 -
A Study of PVX-410, a Cancer Vaccine, and Citarinostat +/- Lenalidomide for Smoldering MM
|
Phase 1 | |
Withdrawn |
NCT01571726 -
Imaging Studies and the Development of Multiple Myeloma
|
Phase 2 |